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Abstract
Acute Respiratory Infections (ARIs) are responsible for considerable morbidity and mortality
worldwide. Documentation of respiratory specimens can help for an appropriate clinical
management with a significant effect on the disease progress in patient, the antimicrobial
therapy used and the risk of secondary spread of infection. Here, we compared the perfor-
mances of four commercial multiplex kits used in French University Hospital diagnostic
microbiology laboratories for the detection of ARI pathogens (i.e., the xTAG Respiratory
Viral Panel Fast, RespiFinder SMART 22, CLART PneumoVir and Fast Track Diagnostics
Respiratory Pathogen 33 kits). We used a standardised nucleic acids extraction protocol
and a comprehensive comparative approach that mixed reference to well established
real-time PCR detection techniques and analysis of convergent positive results. We tested
166 respiratory clinical samples and identified a global high degree of correlation for at
least three of the techniques (xTAG, RespiFinder and FTD33). For these techniques, the
highest Youden’s index (YI), positive predictive (PPV) and specificity (Sp) values were
observed for Core tests (e.g., influenza A [YI:0.86–1.00; PPV:78.95–100.00; Sp:97.32–
100.00] & B [YI:0.44–1.00; PPV:100.00; Sp:100.00], hRSV [YI:0.50–0.99; PPV:85.71–
100.00; Sp:99.38–100.00], hMPV [YI:0.71–1.00; PPV:83.33–100.00; Sp:99.37–100.00],
EV/hRV [YI:0.62–0.82; PPV:93.33–100.00; Sp:94.48–100.00], AdV [YI:1.00; PPV:100.00;
Sp:100.00] and hBoV [YI:0.20–0.80; PPV:57.14–100.00; Sp:98.14–100.00]). The present
study completed an overview of the multiplex techniques available for the diagnosis of
acute respiratory infections.
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Introduction
Acute Respiratory Infections (ARIs) are responsible for considerable morbidity and mortality
worldwide [1]. The precise and rapid documentation of respiratory specimens can lead to a sig-
nificant effect on the disease progress in patients [2] when identification of the causative agents
leads to providing an appropriate therapy administration, but it is also useful for decreasing
the use of unnecessary antimicrobial therapy [3,4] and limiting the risk of secondary spread of
infection [5]. However, ARIs are most often associated with poorly specific clinical presenta-
tions [6] and therefore, their aetiological diagnosis mainly relies on laboratory testing.
Conventional laboratory diagnostic methods have several limitations for routine detection
of respiratory pathogens. For example, culture isolation of viruses of bacteria is poorly sensi-
tive, time consuming and usually too slow to provide a biological result at the acute phase of
the disease [7]; direct immunofluorescence assays and immunochromatographic antigen test-
ing can provide results very rapidly but represent time- and labor-consuming tasks for the for-
mer, and are poorly sensitive for the latter [8,9,10]. Molecular biology testing allows the
detection of a variety of viral and bacterial pathogens within hours, with excellent sensitivity
and specificity and may represent a credible alternative to the aforementioned biological assays.
However, given the number of aetiological agents potentially implicated in ARIs, conventional
monoplex PCR assays are tedious, expensive and require large amounts of biological samples
[10,11]. Consequently, multiplex molecular detection tests have been increasingly developed in
recent years and a number of commercial kits have been proposed to diagnostic microbiology
laboratories, which allow the detection of 12 to 33 different pathogens. This includes the xTAG
Respiratory Viral Panel, Fast or v1, assays (Luminex Molecular Diagnostics, Toronto, Canada);
the FilmArray respiratory viral panel assay (BioFire Diagnostics, Salt Lake City, UT); the Fast
Track Diagnostics Respiratory Pathogen, 21 or 33, assays (Fast Track Diagnostics, Luxem-
bourg); the CLART PneumoVir (Genomica, Coslada, Spain); the RespiFinder, 19 or SMART
22, assay (Pathofinder, Maastricht, Netherlands); the eSensor Respiratory Viral Panel (Gen-
Mark Dx, Carlsbad, CA); the MultiCode-PLx (EraGen Biosciences); the Easyplex respiratory
pathogen 12 kit (Ausdiagnostics, Sydney, Australia); the Seeplex RV15 OneStep ACE Detection
and Pneumobacter ACE Detection (Seegene Inc., Seoul, South Korea); the Magicplex RV Panel
Real-time Test (Seegene Inc); and the ResPlex II Panel v2.0 (Qiagen, Hilden, Germany). Pre-
cisely evaluating such multiplex kits is difficult in the absence of undisputable golden standard
reference techniques for a large number of the pathogens tested. A number of studies have
compared the detection of the molecular multiplex platforms with in-house conventional
molecular methods [11,12,13,14] but since the reference methods vary from study to study
[15], estimating the actual performance of the assays remains difficult. More recently, direct
comparison of commercialised multiplex kits was undertaken, with reference to in-house mul-
tiplex real-time PCR systems [16], or to commercial duplex PCR tests [17].
Here, as a follow-up to these pioneer studies, we compared the performances of four com-
mercial multiplex kits used in French University Hospital diagnostic microbiology laboratories
for the detection of ARI pathogens, i.e., the xTAG Respiratory Viral Panel Fast, RespiFinder
SMART 22, CLART PneumoVir and Fast Track Diagnostics Respiratory Pathogen 33 kits. Our
analysis mainly focussed on viral pathogens that represent the common target of all kits, the
number of bacteria potentially detected varying from 4 (RespiFinder SMART 22) to 12 (Fast
Track Diagnostics Respiratory Pathogen 33), making any sound comparison impossible. We
combined normalised extraction of nucleic acids, "reference" monoplex real-time PCR detec-
tion and a consensus interpretation algorithm to estimate the intrinsic capability of each kit to
detection of the various pathogens tested.
Multiplex Molecular Tests for Respiratory Infections Diagnostics
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Materials and Methods
Nasopharyngeal swabs
Out of the 1,465 patients enrolled in the CoPanFlu-France cohort study [18], 166 presented
with ARI during the 2010 and 2011 influenza epidemic seasons. Nasopharyngeal samples were
available for all these patients and were selected for this study.
The patients' age ranged from 1 month to 79 years (median: 31.2yo).
Broad range multiplex Kits
Four commercial kits for Multiplex detection of respiratory viruses were tested:
- The CLART PneumoVir (PneumoVir) assay is based on PCR-DNAmicro-array detec-
tion. This assay allows the detection of 17 respiratory viruses.
- The Fast Track Diagnostics Respiratory Pathogen 33 (FTD-RP33) version 3 assay is
based on multiplex one-step reverse transcription polymerase chain reactions (RT-PCR)
with probes for detecting 33 respiratory pathogens (21 viruses and 12 bacteria). It was
used with the Bio-Rad CFX96 thermocycler and The SuperScript III Platinum One-Step
Quantitative RT-PCR System without ROX (Invitrogen).
- The xTAG Respiratory Viral Panel Fast (xTagRVP-F) is based on a multiplex RT-PCR
reaction in which the target-specific primers are chimeric, including a terminal Universal
Tag sequence. This allows the detection of 19 different respiratory viruses [4,19] by sort-
ing on a Luminex xMAP instrument [20].
- The RespiFinder SMART 22 (RespiFinder) assay is based on the multiplex ligation-
dependent probe amplification (MLPA) technology, preceded by a pre-amplification step
[20]. Results are analysed by capillary electrophoresis [9]. This assay differentiates 18
respiratory viruses and 4 bacteria in one reaction by melt curve analysis.
The different protocols were performed according to manufacturers’ instructions but the
extraction of nucleic acids was standardised to use a similar molecular substrate in each assay.
One extraction dedicated to each test (each multiplex assay and for the “confirmation tests”)
was performed from one of the identical 100μL aliquots prepared from nasopharyngeal swabs.
The internal controls of each test were included in the dedicated extraction, and their final con-
centration adapted to manufacturers' recommendations. Nucleic acids were extracted using the
EZ1 Virus Mini Kit v2 on the EZ1 advanced XL Biorobot workstation (Qiagen). Elution was
performed in a 90μL volume and nucleic acids were subsequently stored at -80°C before
analysis.
The combination of all systems potentially allowed the detection of 41 respiratory patho-
gens: Influenzavirus A (Inf A) (H3N2, H1N1, H5N1), Influenzavirus B (Inf B), Influenzavirus
C (Inf C), Parainfluenzaviruses (PIV) (1, 2, 3 and 4a/b), human Respiratory Syncytial Virus
(hRSV) (A and B), Enteroviruses (EV), Rhinoviruses (hRV), Adenoviruses (AdV), Parecho-
viruses, human Bocavirus (hBoV), human Coronaviruses (hCoV) (229E, NL63, OC43,
HKU1), human Metapneumovirus (hMPV) (A and B), Cytomegalovirus (CMV), Pneumocystis
jirovecii (PCP),Mycoplasma pneumoniae (Mpneu), Chlamydia pneumoniae (Cpneu), Strepto-
coccus pneumoniae (Spneu), Haemophilus influenzae species (Haeinf),Haemophilus influenzae
type B (HIB), Staphylococcus aureus (Saur),Moraxella catarrhalis (Morax), Bordetella pertusis
(Bord), Klebsiella pneumoniae (Kpneu), Legionella species (Legio) and Salmonella species
(Salm).
Multiplex Molecular Tests for Respiratory Infections Diagnostics
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The spectrum of detection of the different kits is reported in Table 1. Tests allowing the
detection of respiratory pathogens were classified in two different classes: the "Core tests" and
the "Extra tests", the "Core tests" being defined as those corresponding to pathogens detected
by all four kits.
Table 1. Respiratory pathogens detected by each Kit.
Viruses Bacteria
PneumoVir FTD-RP33 xTagRVP-F RespiFinder PneumoVir FTD-RP33 xTagRVP-F RespiFinder
Inf A
p p p
Pneumo jiro
p
H1N1
p p
Myco pneumo
p p
H1N1pdm09
p p
Chlam pneumo
p p
H3N2
p p
Strepto pneumo
p
Inf B
p p p p
Haemo inf sp
p
Inf C
p p
Haemo inf B
p
PIV 1
p p p p
Staph aur
p
PIV 2
p p p p
Morax catarr
p
PIV 3
p p p p
Bord pert
p p
PIV 4
p p p
Klebs pneumo
p
PIV 4 a
p
Legio sp
p p
PIV 4 b
p
Salmo sp
p
hRSV
p
hRSV A
p p p
hRSV B
p p p
EV/ hRV
p p
hRV
p p
EV
p p
AdV
p p p p
EVs
p p p p
hPEV
p
hBoV
p p p p
hCoV 229E
p p p p
hCoV NL63
p p p
hCoV OC43
p p p
hCoV HKU1
p p p
hMPV
p p p p
hMPV A
p
hMPV B
p
CMV
p
Inf A, B, C: Inﬂuenza A, B, C; H1N1: Inﬂuenza A H1N1; H1N1pdm09: Inﬂuenza A H1N1pdm 2009; H3N2: Inﬂuenza A H3N2; PIV 1, 2, 3, 4, 4a, 4b:
Parainﬂuenzavirus 1, 2, 3, 4, 4a, 4b; hRSV: human Respiratory Syncytial Virus; hRSV A, B: human Respiratory Syncytial Virus A, B; EV: Enterovirus;
hRV: human Rhinovirus; AdV: Adenovirus; hBoV: human Bocavirus; hCoV 229E, OC43, NL63, HKU1: human Coronavirus type 229, OC43, NL63, HKU1;
hMPV: human Metapneumovirus; hMPV A, B: human Metapneumovirus A, B; CMV: Cytomegalovirus; EVs: Echovirus; hPeV: human Parechovirus;
Pneumo jiro: Pneumocystis jirovecii; Myco pneumo: Mycoplasma pneumoniae; Chlam pneumo: Chlamydia pneumoniae; Strepto pneumo: Streptococcus
pneumoniae; Haemo inf sp: Haemophilus inﬂuenzae species; Haemo inf B: Haemophilus inﬂuenzae type B; Staph aur: Staphylococcus aureus; Morax
catarr: Moraxella catarrhalis; Bord pert: Bordetella pertussis; Klebs pneumo: Klebsiella pneumoniae; Legio sp: Legionella species; Salmo sp: Salmonella
species; PneumoVir: CLART PneumoVir; FTD-RP33: Fast Track Diagnostics Respiratory Pathogen 33; xTagRVP-F: xTAG Respiratory Viral Panel Fast;
RespiFinder: RespiFinder SMART 22
doi:10.1371/journal.pone.0130378.t001
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Processing of samples and interpretation of results
Firstly, all samples were tested with the four broad range multiplex kits (Fig 1). In addition,
they were systematically tested for Inf A and Inf B using in-house standard real-time RT-PCR
assays [21], and for Core tests (Inf A, Inf B, hRSV, hMPV, EV + hRV, AdV and hBoV) using
the Argene (Respiratory Multi Well System r-gene) low range kit, consisting of 4 Taqman-
based duplex PCR or RT-PCR reactions (Inf A+B, hRSV+hMPV, hRV&EV+cellular control,
AdV+hBoV).
Samples testing negative for a given pathogen with all detection methods were proposed
negative for this pathogen. Samples testing positive for a pathogen with at least 2 different tech-
niques were proposed positive. Samples with discrepant results (positive for one pathogen with
only one detection method) were further processed with "confirmation" assays, consisting of
one or several real-time or nested amplification protocols (Table A in S1 File) and subsequently
declared positive or negative according to the result obtained.
Positive predictive value (PPV), negative predictive value (NPV), Sensitivity, Specificity and
agreement (as evaluated by the Youden’s index) values were calculated for the Core tests of the
kits tested (see below).
Secondly, all samples were analysed according to the results obtained by the four broad
range multiplex kits for Extra tests (S1 Fig): Influenza A H1N1pdm 2009; "seasonal" Influenza
A H1N1; Flu A H5N1; Flu A H3N2; hRSV A/B, hMPV A/B, PIV 1/2/3/4a/4b, PCP and bacteria
(Mpneu, Cpneu, Spneu, Haeinf, HIB, Saur, Morax, Bord, Kpneu, Legio and Salm).
Only results relating to viral pathogens were analysed in depth since a majority of bacterial
pathogens were detected only by the FTD-RP33 test.
A decision tree similar to that used for Core tests was designed and confirmation techniques
were used to confirm or invalidate discrepant results (Table B in S1 File). PPV, Sensitivity,
NPV, and Specificity values were calculated for Extra tests (see below).
Performances of the kits
To compare the performances of the kits, Sensitivity, Specificity and Positive and Negative Pre-
dictive values were calculated. In accordance with the interpretation rules decreed in the previ-
ous section, calculations relied on the following definitions: (i) True Positives were Positive
results confirmed by another kit or a confirmation test; (ii) False Positives were Positive results
that were not confirmed by another kit or a confirmation test; (iii) False Negatives were Nega-
tive results invalidated by at least 2 other kits or 1 kit and 1 confirmation test; (iv) True Nega-
tives were Negative results that were not invalidated by at least 2 other kits or 1 kit and 1
confirmation test.
Virus positive controls and limits of detection
Culture supernatants were obtained from the European virus archive collection (EVA, www.
europeanvirusarchive.com) for Influenza A H1N1 (A/Marseille/9410380/2009), Influenza A
H3N2 (A/Marseille/4781598/2009), Influenza B (B/Marseille/4461097/2008), Influenza C (C/
Leningrad:232/83), Respiratory Syncytial virus type A (Long) and B (Gb2), Rhinovirus
(MAR2007 3813047), Enterovirus (Human Coxsackievirus B3 clinical strain B32679), human
Parechovirus type 3 (UNK), Adenovirus type B (MAR2007 7416184 clinical strain). In the case
of the human Metapneumovirus type A, a sample testing positive using both molecular detec-
tion and direct immunofluorescence was used as a positive control.
Nucleic acids were extracted as described above but using an initial sample volume of 400μL
and an elution volume of 120μL. Tenfold serial dilutions of nucleic acids were performed and
tested using the relevant in-house "confirmation" real time PCR or RT-PCR assays (S1 File).
Multiplex Molecular Tests for Respiratory Infections Diagnostics
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Fig 1. Decision tree (algorithm used for Core tests). (Inf A: Influenza A, Inf B: Influenza B, hRSV: human
Respiratory Syncytial Virus, hMPV: humanMetapneumovirus, EV + hRV:; Enterovirus + human Rhinovirus,
AdV: Adenovirus and hBoV: human Bocavirus).
doi:10.1371/journal.pone.0130378.g001
Multiplex Molecular Tests for Respiratory Infections Diagnostics
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The last three dilutions allowing unambiguous detection (i.e., the lowest dilution had a Ct at 33
and the highest dilution had a Ct between 37 and 40) were used to create a panel, which was
subsequently used to evaluate the limit of detection of the 4 broad range multiplex kits.
Ethics statement
The CoPanFlu-France cohort protocol was approved by the French ethics committee (“Comité
de Protection des Personnes Ile-de-France I”) on 8 September 2009. All study participants pro-
vided written informed consent [18].
Results
The analysis of 166 Nasopharyngeal samples using a combination of four commercial broad
range multiplex kits and of confirmation tests provided confirmed aetiological viral diagnosis
for 87 samples (52%), including 8 samples (4.8%) with confirmed dual infection (see details in
Table 2).
The distribution of confirmed positive detections provided the following results: Enterovi-
rus/Rhinovirus: 34 (39.1%); Influenza A H1N1 2009: 17 (19.5%); Coronavirus: 13 (14.9%);
Influenza B: 9 (10%); Metapneumovirus: 7 (8.1%); Respiratory Syncytial Virus: 6 (6.9%); Boca-
virus: 5 (5.7%); Parainfluenzaviruses: 3 (3.5%); Adenovirus: 1 (1.1%).
Performances of the four commercial broad range multiplex kits
The performances of the kits for the detection of specific pathogens are presented in Table 3.
Regarding the detection of Influenza A viruse(s), the sensitivity and PP values ranged from
88.2% and 79% respectively for the PneumoVir kit to 100% for the FTD-RP33 kit. Regarding
Influenza B, the best sensitivity was observed for the RespiFinder kit (100%). It was under 80%
for the PneumoVir and FTD-RP33 kits and under 50% for the xTagRVP-F kit. PP values were
at 100% for all kits except the PneumoVir kit (87.5%).
Globally, the performances of the PneumoVir kit were hindered by the existence of false
positive results for a proportion of the pathogens tested, but also of false negative results for the
most common pathogens and in particular human Rhinoviruses/Enteroviruses. The perfor-
mances of the xTagRVP-F kit were hampered by its low sensitivity for the detection of Influ-
enza B, human bocaviruses and human coronaviruses, but the kit was associated with high PP
values (very few false positives). This profile is somewhat similar to that of the FTD-RP33 kit
that exhibited high PP values and perfectible sensitivity for the detection of Influenza B, Para-
influenzaviruses, human Respiratory Syncytial virus and human Rhinoviruses/ Enteroviruses.
The RespiFinder Kit displayed the highest overall sensitivity values, associated with high PP
values. Its lowest performances were for human Metapneumoviruses (sensitivity: 71.4%) and
Parainfluenzaviruses (66.6%, similar with other kits).
Regarding the global performances of the kits, the Positive Predictive values were>90% for
three of the four kits (xTagRVP-F, FTD-RP33 and RespiFinder) (Table 4). The highest overall
specificity was observed for the FTD-RP33 kit (94.4%), with a 100% score for five common
pathogens (Influenzaviruses A and B, Parainfluenzaviruses, human Respiratory Syncytial
viruses, human Rhinoviruses/Enteroviruses). The most important differences between the kits
tested were identified for the overall sensitivity (ranging from 63.9% for the PneumoVir Kit to
88.4% for the RespiFinder Kit) and for the Negative Predictive Value (ranging from 70% for
the PneumoVir Kit to 85.3% for the RespiFinder Kit).
The Youden’s index, which summarise the performance of a diagnostic test, was globally
strong (> 0.60) except for the PneumoVir kit (0.48).
Multiplex Molecular Tests for Respiratory Infections Diagnostics
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Table 2. Viral etiologies identified and bacterial results.
Viruses (Conﬁrmed results) Nb
hRV 27
EV 1
EV/RV* 6
H1N1pdm09 17
Inf B 9
hBoV 5
hCoV HKUI 4
hCoV NL63 4
hCoV OC43 4
hCoV 229E 1
hMPV A 4
hMPV B 3
hRSV A 4
hRSV B 2
PIV 2 2
PIV 1 1
AdV 1
Total number of virus detected 95
EV/hRV+ hBoV 1
H1N1pdm09 + RV 1
Inf B + hBoV 1
Inf B + RV 1
PIV 1 + hCoV HKUI 1
EV/hRV+ hMPV A 1
hRSV A + hMPV A 1
hRSV B+ AdV 1
Total number of viral dual infections 8
Total number of viral positive samples 87
Percentage of viral positive samples (n = 166) 52.40%
Bacteria (Not conﬁrmed results) ** Nb
Total number of bacteria detected 104
Total number of bacterial dual infections 14
Total number of bacterial co-infections (at least 2 other bacteria) 6
Total number of bacteria positive samples 77
Percentage of bacteria positive samples (n = 166) 25.30%
Total number of co-infections (Virus/bacteria) 40
Total number of positive samples (conﬁrmed for viruses but not for bacteria) 124
Percentage of positive samples (n = 166) 74.70%
Inf A, B: Inﬂuenza A, B; H1N1: Inﬂuenza A H1N1; H1N1pdm09: Inﬂuenza A H1N1pdm 2009; PIV 1, 2:
Parainﬂuenzavirus 1, 2; hRSV A, B: human Respiratory Syncytial Virus A, B; EV: Enterovirus; hRV: human
Rhinovirus; AdV: Adenovirus; hBoV: human Bocavirus; hCoV 229, OC43, NL63, HKU1: human
Coronavirus type 229, OC43, NL63, HKU1; hMPV A, B: human Metapneumovirus A, B.
(*) EV/ hRV detected no determined for Enterovirus or human Rhinovirus
(**) Bacteria etiologies identiﬁed are shown in supplementary information (S1 Table)
doi:10.1371/journal.pone.0130378.t002
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Limits of detection of the four commercial broad range multiplex kits
Results are presented in Fig 2 and show that, at the highest dilution proposed, the RespiFinder
kit detected 8 pathogens (out of the 9 tested), whilst the PneumoVir kits detected 6 (out of 10
tested), the xTagRVP-F kits detected 5 (out of 9 tested) and the FTD-RP33 detected 4 (out of
11 tested).
Discussion
We have compared 4 commercialised multiplex PCR techniques for the detection of respira-
tory pathogens using standardised nucleic acid extracts from French patients presenting with
ARIs in 2010 and 2011. Our study mainly focussed on viral pathogens.
There is previous significant information relating to the comparison of the performances of
the kits studied with conventional diagnostic technique. This includes: (i) direct immunofluo-
rescence, viral culture, and home-brew PCR in the case of the CLART PneumoVir assay [22];
Table 4. Global comparison of PPV, Sensitivity, NPV, Specificity and Youden's index values between
kits for all tests.
PneumoVir xTagRVP-F FTD-RP33 RespiFinder
Number of true positives (TP) 53 69 74 84
Number of false positives (FP) 13 6 4 7
Number of true negatives (TN) 70 65 67 64
Number of false negatives (FN) 30 26 21 11
PPV 80.30% 92.00% 94.87% 92.31%
Sensitivity 63.86% 72.63% 77.89% 88.42%
NPV 70.00% 71.43% 76.14% 85.33%
Speciﬁcity 84.34% 91.55% 94.37% 90.14%
Youden's index 0.48 0.64 0.72 0.79
Criteria for the deﬁnition of true positives, false positives, true negatives and false negatives are provided in
the 'Materials and Methods section', 'Performances of the kits' sub-section. PneumoVir: CLART
PneumoVir; xTagRVP-F: xTAG Respiratory Viral Panel Fast; FTD-RP33: Fast Track Diagnostics
Respiratory Pathogen 33; RespiFinder: RespiFinder SMART 22
doi:10.1371/journal.pone.0130378.t004
Fig 2. Estimate of detection limit of the different kits. Inf A H1N1: Influenza A H1N1 (A/Marseille/9410380/
2009), Inf A H3N2: Influenza A H3N2 (A/Marseille/4781598/2009), Inf B: Influenza B (B/Marseille/4461097/
2008), Inf C: Influenza C (C/Leningrad:232/83), hRSV A and B: human Respiratory Syncytial virus type A
(Long) and B (Gb2), hRV: Rhinovirus (MAR2007 3813047), EV Cox B3: Enterovirus (Human Coxsackievirus
B3 clinical strain B32679), hPeV: human Parechovirus type 3 (UNK), AdV B: Adenovirus type B (MAR2007
7416184 clinical strain), and hMPV A: humanMetapneumovirus type A.
doi:10.1371/journal.pone.0130378.g002
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(ii) home-brew PCR, direct immunofluorescence, and viral culture in the case of the xTAG
Respiratory Viral Panel Fast assay [7,19,23–25]; (iii) home-brew PCR, and in-house multiplex
real-time PCR in the case of the Fast Track Diagnostics Respiratory Pathogen assay [13,16];
(iv) home-brew PCR and viral culture in the case of the RespiFinder SMART 22 assay [26,27].
In addition, previous studies included comparison with other multiplex commercial kits:
xTAG Respiratory Viral Panel Fast assay versus FilmArray respiratory viral panel, ResPlex II
Panel v2.0, MultiCode-PLx, Seeplex RV15 OneStep ACE Detection and Pneumobacter ACE
Detection and xTAG Respiratory Viral Panel v1 kits [7,23,25]; RespiFinder SMART 22 assay
versus Seeplex RV15 OneStep ACE Detection and Pneumobacter ACE Detection, ResPlex II
Panel v2.0, RespiFinder 19 kits [2,9,26,27]; Fast Track Diagnostics Respiratory Pathogen 21
versus xTAG Respiratory Viral Panel fast and Easyplex respiratory pathogen 12 kits [16]. The
most complete study compared six commercialised techniques, i.e., the RespiFinder SMART
22, Seeplex RV15 OneStep ACE Detection and Pneumobacter ACE Detection, Magicplex RV
Panel Real-time Test, CLART PneumoVir, xTAG Respiratory Viral Panel fast and ResPlex II
Panel v2.0 kits [17].
Globally, the literature indicates that multiplex molecular techniques compare favourably
with traditional diagnostic technique. They can be (at least partially) automated, are highly
reproducible and are generally more sensitive.
However, a first difficult issue for comparing respiratory pathogens multiplex tech-
niques is the absence of gold standard for the detection of respiratory pathogens. If we refer
only to the ability of a technique to detect a pathogen or some of its molecular components in
biological samples, some newly developed molecular techniques may be more sensitive than
the reference techniques, (i.e., some "false positives", referring to the reference technique, may
be true positives that have not been detected by this reference method). This situation may be
met when the new technique is able to detect viral variants that could not be detected by previ-
ous methods and, in that case, corresponds to an actual improvement of the technique if the
variants detected are true pathogens that can be implicated in ARIs. However, it can also be
met when the new technique is able to detect a lower viral load. The actual clinical impact of an
improved detection of low viral loads in respiratory samples has not been accurately evaluated
and its medical significance at the acute phase of ARIs obviously requires to be further docu-
mented. Altogether, this indicates that the interpretation of evaluation scores should remain
careful and open-minded. Accordingly, we have tried to build a comprehensive approach of
the comparison of diagnostic kits that mixed reference to well established–and clinically evalu-
ated- real-time PCR detection techniques (this included in the current study the Argene Respi-
ratory Multi Well System r-gene low range kit for Core tests, which has been used for years for
routine detection in medical virology laboratories; and a series of published home-brewed tech-
niques) and analysis of convergent positive results. For the latter, we considered that, given (i)
the intrinsic high specificity of molecular amplification techniques, and (ii) the fact that the
techniques compared used different technologies and amplification primers, the probability of
obtaining false positive results with two different techniques for the same sample was negligible
for an evaluation purpose. Consequently, samples in which a given pathogen was detected
independently by two different techniques were declared positive for this pathogen, otherwise
it was declared negative. We cannot exclude that a few samples were wrongly assigned a nega-
tive result (if a specific technique performed better than all others for a given pathogen), but
the high degree of convergence between the different techniques suggests that the number of
"false negative" results that could have been potentially generated is limited.
A second difficult issue for comparing respiratory pathogens multiplex techniques is the
choice of the panel of samples tested. The nature and frequency of pathogens present in the
samples tested are highly dependent on the epidemiological circumstances and on the
Multiplex Molecular Tests for Respiratory Infections Diagnostics
PLOS ONE | DOI:10.1371/journal.pone.0130378 June 24, 2015 12 / 17
populations tested, and have an obvious influence on the results of the analysis, e.g., the low
number or absence of positive samples for some viruses represents in most of the studies an
obvious obstacle for accurate comparisons. In the current study, we tested patients with ARIs
from all age groups recruited in a household cohort that aimed at providing a picture of the
French general population. This means that, in comparison with previous hospital-based stud-
ies, the paediatric population was under-represented and the clinical presentations were
milder. In addition, the specific period studied (2010–2011) was associated with the predomi-
nant circulation of the pandemic H1N1 variant of the influenza A virus. Accordingly, the low
number or absence of parainfluenza virus, human coronavirus type 229E, H3N2 influenza A
virus, influenza C virus, human adenovirus and human parechovirus infections did not allow a
significant comparison of kits for these pathogens. This is important to notice since in previous
studies the low number of positive samples for some pathogens may have concealed the poor
performances of some kits for detecting these pathogens (e.g., the case of Adenoviruses for the
xTAG Respiratory Viral Panel fast assay [9,17,25]).
A third difficult issue for comparing respiratory pathogens multiplex techniques relies
in the different spectra of detection and precision of identification offered by the various com-
mercialised kits. To take this aspect into account, we have identified "Core tests", i.e., a series of
common pathogens detected by all kits (Inf A, Inf B, hRSV, hMPV, EV + hRV, AdV and
hBoV). We have also limited our analysis to viral pathogens since bacterium detection was
absent or very limited in 3 of the 4 kits tested. The simultaneous detection of bacteria and
viruses represents a theoretical great advantage in terms of clinical management (e.g., for deter-
mining the appropriateness of starting an antibiotic treatment). However, it is noticeable that,
in the current study, bacteria detection provided a large number of positive results, potentially
shifting the rate of aetiological elucidation from 52% to>77% in the panel studied. Obviously,
this deserves further in depth investigations, which should include samples from both ARIs
and paired asymptomatic individuals. Determining the actual imputability of bacterial detec-
tion in the occurrence of ARIs may be difficult to achieve from qualitative results and clinically
relevant interpretation algorithms remain to be established. As noted above, the detection of
low pathogen loads may be an issue for viruses, but the case of bacteria is specifically difficult
due to the frequent asymptomatic carriage of potentially pathogenic bacteria.
For Core tests, we identified an important degree of correlation between the performance of
the xTAG Respiratory Viral Panel fast, the Fast Track Diagnostics Respiratory Pathogen 33
and the RespiFinder SMART 22 assays (Youden’s index: 0.67; 0.73 and 0.83, respectively)
(Table 5). The CLART PneumoVir assay exhibited the most divergent performance (global
Core tests Youden’s index value: 0.51; global Core tests sensitivity and specificity values: 63.3%
and 87.4%, respectively), despite previous favourable performance by comparison with home-
brew PCR techniques [22]. When examined in more details (Table 3), the sensitivity values for
Core tests compared with those of the other kits, except for human Rhinoviruses/Enteroviruses
(sensitivity: 41.2%) and human Bocaviruses (40%). There was also a trend for the existence of
false positive results for Influenza A and Metapneumovirus tests, which altered the global posi-
tive predictive value of the kit (81.9% vs>90% for all other kits). False positive results may
hypothetically be related to the fact that the technique includes an open-tube post amplification
step, potentially associated with an increased risk of PCR contamination. In serial dilution
tests, 4 (Inf A H3N2, Inf B, Inf C and hMPV A) out of the 10 pathogens detected in the most
concentrated dilution tested negative at dilutions 10−1 and 10−2 (Fig 2).
Our study globally confirms the previously observed good performances of the xTAG Respi-
ratory Viral Panel Fast [2,9,7,15,17,23–25,28]. For Core tests, the global sensitivity and specific-
ity values were 73.4% and 93.1%, respectively (Table 5). The poorest results were observed for
influenza A positive predictive value (78.9%) and influenza B and human bocavirus sensitivity
Multiplex Molecular Tests for Respiratory Infections Diagnostics
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values (44.4% and 20%, respectively). In serial dilution tests, out of the 9 pathogens detected in
the most concentrated dilution, one (hMPV A) tested negative at dilution 10−1 and 4 (Inf B,
hRSV A, hRSV B and hMPV A) at dilution 10−2.
The Fast Track Diagnostics Respiratory pathogens 33 kit performed well for Core tests
(global sensitivity and specificity values were 75.9% and 96.5%) (Table 5). The excellent speci-
ficity values (the highest in the panel tested) may be related in part to the simple and safe real-
time PCR format of the technique, which does not require any post-PCR manipulation.
Amongst Core tests, and in agreement with previous findings [13], the lowest sensitivity values
were observed for human Respiratory Syncytial Virus and Enterovirus/Rhinovirus (50% and
61.8%, respectively). In serial dilution tests, out of the 11 pathogens detected in the most con-
centrated dilution, 3 (Inf B and C, hRSV B) tested negative at dilution 10−1 and 7 (Inf B and C,
hRSV B, EV Cox B3, hPeV, hAdV B and hMPV A) at dilution 10−2, in coherence with previous
observations [13].
The RespiFinder SMART 22 assay, provided for Core tests both the highest Youden’s index
performance values (global Core tests Youden’s index value: 0.83) and the best global sensitiv-
ity (87.3%). It also was associated with an excellent specificity (95.4%), in agreement with pre-
vious evaluations [2,9,26,27]. Amongst Core tests, the lowest sensitivity value was observed for
human Metapneumovirus (71.4%). The kit also provided the best results in serial dilution tests:
of the 9 pathogens detected in the most concentrated dilution, all tested positive at dilution
10−1 and 1 (hMPV A) tested negative at dilution 10−2.
Conclusion
The present study identified a high degree of correlation for at least three of the techniques and
completed an overview of the multiplex techniques available for the diagnosis of acute respira-
tory infections. All of the kits evaluated performed properly for Core tests and Youden’s index,
positive predictive and specificity values were systematically higher for Core tests than for
Extra tests. Significant differences in the ability of the kits to detect low viral loads were identi-
fied, but the medical implications of this observation remain to be evaluated. The range of
detected pathogens, the technology used for PCR product revelation, the laboratory organiza-
tion and other issues, such as sample through-put, staffing levels and staff expertise, clinicians’
Table 5. Global comparison of PPV, Sensitivity, NPV, Specificity and Youden's index values between
kits for Core tests (Inf A, Inf B, hRSV, hMPV, EV + hRV, AdV and hBoV).
PneumoVir xTagRVP-F FTD-RP33 RespiFinder
Number of true positives (TP) 50 58 60 69
Number of false positives (FP) 11 6 3 4
Number of true negatives (TN) 76 81 84 83
Number of false negatives (FN) 29 21 19 10
PPV 81.97% 90.63% 95.24% 94.52%
Sensitivity 63.29% 73.42% 75.95% 87.34%
NPV 72.38% 79.41% 81.55% 89.25%
Speciﬁcity 87.36% 93.10% 96.55% 95.40%
Youden's index 0.51 0.67 0.73 0.83
Criteria for the deﬁnition of true positives, false positives, true negatives and false negatives are provided in
the 'Materials and Methods section', 'Performances of the kits' sub-section.PneumoVir: CLART PneumoVir;
xTagRVP-F: xTAG Respiratory Viral Panel Fast; FTD-RP33: Fast Track Diagnostics Respiratory Pathogen
33; RespiFinder: RespiFinder SMART 22
doi:10.1371/journal.pone.0130378.t005
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expectations and overall funding structures appear as determinant features for the selection of
a kit.
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